{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:22:47Z","timestamp":1792794167109,"version":"4.5.0"},"reference-count":114,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Inflammopharmacol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10787-025-02027-y","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T17:28:47Z","timestamp":1771349327000},"page":"1317-1330","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Psoriasis beyond the skin: systemic inflammation as a bridge to metabolic and hepatic comorbidities"],"prefix":"10.1007","volume":"34","author":[{"family":"Karmbir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheikh Mohammad","family":"Faisal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj Kumar","family":"Narang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balak Das","family":"Kurmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirandeep","family":"kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8185-1381","authenticated-orcid":false,"given":"Amit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"issue":"11","key":"2027_CR1","doi-asserted-by":"publisher","first-page":"910","DOI":"10.2174\/1389200219666180416162942","volume":"19","author":"T Akhtar","year":"2018","unstructured":"Akhtar T, Wani WY, Kamal MA, Kaur R (2018) Role of angiogenic growth factors in psoriasis: a review. Curr Drug Metab 19(11):910\u2013916","journal-title":"Curr Drug Metab"},{"key":"2027_CR2","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.3389\/fimmu.2018.01549","volume":"9","author":"C Albanesi","year":"2018","unstructured":"Albanesi C, Madonna S, Gisondi P, Girolomoni G (2018) The interplay between keratinocytes and immune cells in the pathogenesis of psoriasis. Front Immunol 9:1549","journal-title":"Front Immunol"},{"key":"2027_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.medmic.2025.100126","volume":"25","author":"N Amalia","year":"2025","unstructured":"Amalia N, Wicaksono D, Wiyarta E, Rampengan DDCH, Darmawan H, Aditya MR et al (2025) The gut-skin axis in psoriasis: evidence-based insights from a meta-analysis on probiotics-synbiotics-mediated microbiota interventions. Med Microecol 25:100126","journal-title":"Med Microecol"},{"issue":"5","key":"2027_CR4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1155\/MI.2005.273","volume":"2005","author":"O Arican","year":"2005","unstructured":"Arican O, Aral M, Sasmaz S, Ciragil P (2005) Serum levels of TNF-\u03b1, IFN-\u03b3, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005(5):273\u2013279","journal-title":"Mediators Inflamm"},{"key":"2027_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.696597","volume":"8","author":"S Arora","year":"2021","unstructured":"Arora S, Das P, Arora G (2021) Systematic review and recommendations to combine newer therapies with conventional therapy in psoriatic disease. Front Med 8:696597","journal-title":"Front Med"},{"key":"2027_CR6","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S227896","author":"B Aydin","year":"2020","unstructured":"Aydin B, Arga KY, Karadag AS (2020) Omics-driven biomarkers of psoriasis: recent insights, current challenges, and future prospects. Clin Cosmet Investig Dermatol. https:\/\/doi.org\/10.2147\/CCID.S227896","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"1","key":"2027_CR7","volume":"2019","author":"F Bai","year":"2019","unstructured":"Bai F, Li GG, Liu Q, Niu X, Li R, Ma H (2019) Short-term efficacy and safety of IL-17, IL-12\/23, and IL-23 inhibitors brodalumab, secukinumab, ixekizumab, ustekinumab, guselkumab, tildrakizumab, and risankizumab for the treatment of moderate to severe plaque psoriasis: a systematic review and network meta-analysis of randomized controlled trials. J Immunol Res 2019(1):2546161","journal-title":"J Immunol Res"},{"key":"2027_CR8","doi-asserted-by":"crossref","unstructured":"Balak DM, Piaserico S, Kasujee I. Non-alcoholic fatty liver disease (NAFLD) in patients with psoriasis: a review of the hepatic effects of systemic therapies. Psoriasis: Targets and Therapy. 2021:151\u201368.","DOI":"10.2147\/PTT.S342911"},{"key":"2027_CR9","doi-asserted-by":"crossref","unstructured":"Balato A, Balato N, Megna M, Schiattarella M, Lembo S, Ayala F. Pathogenesis of psoriasis: the role of pro-inflammatory cytokines produced by keratinocytes: IntechOpen London, UK; 2012.","DOI":"10.5772\/26163"},{"issue":"2","key":"2027_CR10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.cyto.2014.12.014","volume":"73","author":"J Baliwag","year":"2015","unstructured":"Baliwag J, Barnes DH, Johnston A (2015) Cytokines in psoriasis. Cytokine 73(2):342\u2013350","journal-title":"Cytokine"},{"issue":"4","key":"2027_CR11","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s40257-024-00857-0","volume":"25","author":"F Bellinato","year":"2024","unstructured":"Bellinato F, Maurelli M, Geat D, Girolomoni G, Gisondi P (2024) Managing the patient with psoriasis and metabolic comorbidities. Am J Clin Dermatol 25(4):527\u2013540","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"2027_CR12","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1080\/14712598.2022.2100219","volume":"22","author":"W-H Boehncke","year":"2022","unstructured":"Boehncke W-H, Brembilla NC (2022) Pathogenesis-oriented therapy of psoriasis using biologics. Expert Opin Biol Ther 22(12):1463\u20131473","journal-title":"Expert Opin Biol Ther"},{"key":"2027_CR13","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3389\/fimmu.2018.01682","volume":"9","author":"NC Brembilla","year":"2018","unstructured":"Brembilla NC, Senra L, Boehncke W-H (2018) The IL-17 family of cytokines in psoriasis: IL-17A and beyond. Front Immunol 9:1682","journal-title":"Front Immunol"},{"key":"2027_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.621956","volume":"12","author":"H Bugaut","year":"2021","unstructured":"Bugaut H, Aractingi S (2021) Major role of the IL17\/23 axis in psoriasis supports the development of new targeted therapies. Front Immunol 12:621956","journal-title":"Front Immunol"},{"issue":"7","key":"2027_CR15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s00011-019-01238-8","volume":"68","author":"C Cataldi","year":"2019","unstructured":"Cataldi C, Mari NL, Lozovoy MAB, Martins LMM, Reiche EMV, Maes M et al (2019) Proinflammatory and anti-inflammatory cytokine profiles in psoriasis: use as laboratory biomarkers and disease predictors. Inflamm Res 68(7):557\u2013567","journal-title":"Inflamm Res"},{"issue":"3","key":"2027_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","volume":"32","author":"W-K Chan","year":"2023","unstructured":"Chan W-K, Chuah K-H, Rajaram RB, Lim L-L, Ratnasingam J, Vethakkan SR (2023) Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review. J Obes Metab Syndr 32(3):197","journal-title":"J Obes Metab Syndr"},{"issue":"1","key":"2027_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s13555-020-00466-9","volume":"11","author":"G Chen","year":"2021","unstructured":"Chen G, Chen Z-m, Fan X-y, Jin Y-l, Li X, Wu S-r et al (2021) Gut\u2013brain\u2013skin axis in psoriasis: a review. Dermatol Ther 11(1):25\u201338","journal-title":"Dermatol Ther"},{"issue":"6","key":"2027_CR18","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1111\/j.1365-2133.2010.09992.x","volume":"163","author":"S Coimbra","year":"2010","unstructured":"Coimbra S, Oliveira H, Reis F, Belo L, Rocha S, Quintanilha A et al (2010) Interleukin (IL)-22, IL-17, IL-23, IL-8, vascular endothelial growth factor and tumour necrosis factor-\u03b1 levels in patients with psoriasis before, during and after psoralen\u2013ultraviolet A and narrowband ultraviolet B therapy. Br J Dermatol 163(6):1282\u20131290","journal-title":"Br J Dermatol"},{"issue":"4","key":"2027_CR19","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/j.1365-4632.2011.05154.x","volume":"51","author":"S Coimbra","year":"2012","unstructured":"Coimbra S, Figueiredo A, Castro E, Rocha-Pereira P, Santos-Silva A (2012) The roles of cells and cytokines in the pathogenesis of psoriasis. Int J Dermatol 51(4):389\u2013398","journal-title":"Int J Dermatol"},{"issue":"5","key":"2027_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25052660","volume":"25","author":"DO Costache","year":"2024","unstructured":"Costache DO, Blejan H, Cojocaru DL, Ioni\u021b\u0103 GA, Poenaru M, Constantin MM et al (2024) Intersecting pathways: nonalcoholic fatty liver disease and psoriasis duet\u2014a comprehensive review. Int J Mol Sci 25(5):2660","journal-title":"Int J Mol Sci"},{"key":"2027_CR21","doi-asserted-by":"crossref","unstructured":"Dand N, Mahil SK, Capon F, Smith CH, Simpson MA, Barker JN. Psoriasis and genetics. Acta dermato-venereologica. 2020;100(100-year theme: Psoriasis):54\u201364.","DOI":"10.2340\/00015555-3384"},{"issue":"2","key":"2027_CR22","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.det.2011.11.005","volume":"30","author":"LK DeLong","year":"2012","unstructured":"DeLong LK, Chen SC (2012) Future directions in dermatology quality of life measures. Dermatol Clin 30(2):343\u2013347","journal-title":"Dermatol Clin"},{"key":"2027_CR23","doi-asserted-by":"publisher","first-page":"1335551","DOI":"10.3389\/fmed.2024.1335551","volume":"11","author":"S Dong","year":"2024","unstructured":"Dong S, Li D, Shi D (2024) Skin barrier-inflammatory pathway is a driver of the psoriasis-atopic dermatitis transition. Front Med 11:1335551","journal-title":"Front Med"},{"issue":"8","key":"2027_CR24","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1111\/jdv.16273","volume":"34","author":"A Egeberg","year":"2020","unstructured":"Egeberg A, Gisondi P, Carrascosa JM, Warren RB, Mrowietz U (2020) The role of the interleukin-23\/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. J Eur Acad Dermatol Venereol 34(8):1695\u20131706","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2027_CR25","volume":"2018","author":"M Fiore","year":"2018","unstructured":"Fiore M, Leone S, Maraolo AE, Berti E, Damiani G (2018) Liver illness and psoriatic patients. BioMed Res Int 2018(1):3140983","journal-title":"BioMed Res Int"},{"issue":"6","key":"2027_CR26","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s11926-007-0075-1","volume":"9","author":"E Fitch","year":"2007","unstructured":"Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A (2007) Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep 9(6):461\u2013467","journal-title":"Curr Rheumatol Rep"},{"issue":"21","key":"2027_CR27","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.3390\/ijms20215424","volume":"20","author":"M Furue","year":"2019","unstructured":"Furue M, Hashimoto-Hachiya A, Tsuji G (2019) Aryl hydrocarbon receptor in atopic dermatitis and psoriasis. Int J Mol Sci 20(21):5424","journal-title":"Int J Mol Sci"},{"issue":"8","key":"2027_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13082441","volume":"13","author":"AJ Garc\u00eda-Malinis","year":"2024","unstructured":"Garc\u00eda-Malinis AJ, P\u00e9rez-Gilaberte JB, Gracia-Caza\u00f1a T, Gonz\u00e1lez Garc\u00eda MP, Planas Linares D, Gilaberte Y (2024) The impact of shared assistance between dermatology and internal medicine on patients with psoriasis. J Clin Med 13(8):2441","journal-title":"J Clin Med"},{"issue":"10275","key":"2027_CR29","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/S0140-6736(21)00184-7","volume":"397","author":"K Ghoreschi","year":"2021","unstructured":"Ghoreschi K, Balato A, Enerb\u00e4ck C, Sabat R (2021) Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet 397(10275):754\u2013766","journal-title":"Lancet"},{"issue":"4","key":"2027_CR30","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1111\/j.1365-2133.2012.11099.x","volume":"167","author":"G Girolomoni","year":"2012","unstructured":"Girolomoni G, Mrowietz U, Paul C (2012) Psoriasis: rationale for targeting interleukin-17. Br J Dermatol 167(4):717\u2013724","journal-title":"Br J Dermatol"},{"issue":"11","key":"2027_CR31","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.3390\/ijms18112427","volume":"18","author":"P Gisondi","year":"2017","unstructured":"Gisondi P, Del Giglio M, Girolomoni G (2017) Treatment approaches to moderate to severe psoriasis. Int J Mol Sci 18(11):2427","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2027_CR32","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.clindermatol.2017.09.005","volume":"36","author":"P Gisondi","year":"2018","unstructured":"Gisondi P, Fostini AC, Foss\u00e0 I, Girolomoni G, Targher G (2018) Psoriasis and the metabolic syndrome. Clin Dermatol 36(1):21\u201328","journal-title":"Clin Dermatol"},{"issue":"6","key":"2027_CR33","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1001\/archderm.1991.01680050071006","volume":"127","author":"T Gomi","year":"1991","unstructured":"Gomi T, Shiohara T, Munakata T, Imanishi Ki, Nagashima M (1991) Interleukin 1a, tumor necrosis factor a, and interferon? in psoriasis. Arch Dermatol 127(6):827\u2013830","journal-title":"Arch Dermatol"},{"key":"2027_CR34","doi-asserted-by":"publisher","first-page":"175628482513358","DOI":"10.1177\/17562848251335824","volume":"18","author":"J Gonz\u00e1lez Fern\u00e1ndez","year":"2025","unstructured":"Gonz\u00e1lez Fern\u00e1ndez J, Prieto-Torres L, Ara Mart\u00edn M, Mart\u00ednez-Dom\u00ednguez SJ (2025) MASLD and liver fibrosis in patients with psoriasis receiving IL-17 or IL-23 inhibitors: a systematic review. Ther Adv Gastroenterol 18:17562848251335824","journal-title":"Ther Adv Gastroenterol"},{"key":"2027_CR35","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2025.2514605","author":"E Grueso Navarro","year":"2025","unstructured":"Grueso Navarro E, Lucendo AJ (2025) Metabolic dysfunction-associated steatotic liver disease in inflammatory bowel disease: prevalence, risk factors, pathophysiological pathways and clinical consequences. Expert Rev Clin Immunol. https:\/\/doi.org\/10.1080\/1744666X.2025.2514605. ((just-accepted))","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"2027_CR36","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1007\/s12016-025-09093-8","volume":"68","author":"EJ Han","year":"2025","unstructured":"Han EJ, Ahn J-S, Chae YJ, Chung H-J (2025) Immunomodulatory roles of Faecalibacterium prausnitzii and Akkermansia muciniphila in autoimmune diseases: mechanistic insights and therapeutic potential. Clin Rev Allergy Immunol 68(1):77","journal-title":"Clin Rev Allergy Immunol"},{"key":"2027_CR37","doi-asserted-by":"publisher","first-page":"711060","DOI":"10.3389\/fimmu.2021.711060","volume":"12","author":"Y Hao","year":"2021","unstructured":"Hao Y, Zhu Y-J, Zou S, Zhou P, Hu Y-W, Zhao Q-X et al (2021) Metabolic syndrome and psoriasis: mechanisms and future directions. Front Immunol 12:711060","journal-title":"Front Immunol"},{"key":"2027_CR38","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jaut.2015.07.008","volume":"64","author":"JL Harden","year":"2015","unstructured":"Harden JL, Krueger JG, Bowcock AM (2015) The immunogenetics of psoriasis: a comprehensive review. J Autoimmun 64:66\u201373","journal-title":"J Autoimmun"},{"issue":"4","key":"2027_CR39","first-page":"517","volume":"19","author":"J Heitmann","year":"2021","unstructured":"Heitmann J, Frings VG, Geier A, Goebeler M, Kerstan A (2021) Non-alcoholic fatty liver disease and psoriasis: Is there a shared proinflammatory network? JDDG J Dtsch Dermatol Ges 19(4):517\u2013528","journal-title":"JDDG J Dtsch Dermatol Ges"},{"issue":"2","key":"2027_CR40","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1177\/24755303211047479","volume":"7","author":"JJ Hong","year":"2022","unstructured":"Hong JJ, Hadeler EK, Mosca ML, Brownstone ND, Bhutani T, Liao WJ (2022) TNF-alpha inhibitors and ustekinumab for the treatment of psoriasis: therapeutic utility in the era of IL-17 and IL-23 inhibitors. J Psoriasis Psoriatic Arthritis 7(2):79\u201392","journal-title":"J Psoriasis Psoriatic Arthritis"},{"key":"2027_CR41","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/978-3-031-33548-8_20","volume-title":"Nonalcoholic fatty liver disease and psoriasis. Essentials of non-alcoholic fatty liver disease: complications and extrahepatic manifestations","author":"L Huiban","year":"2023","unstructured":"Huiban L, Trifan A, Stanciu C (2023) Nonalcoholic fatty liver disease and psoriasis. Essentials of non-alcoholic fatty liver disease: complications and extrahepatic manifestations. Springer, Berlin, pp 229\u2013241"},{"key":"2027_CR42","unstructured":"Jadali Z, Eslami M, Bayatian P, Mirshafiei A, SALEHIE NA, Izad M, et al. Th1\/Th2 cytokines in psoriasis. 2007."},{"issue":"8","key":"2027_CR43","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s00403-007-0775-4","volume":"299","author":"SP Jariwala","year":"2007","unstructured":"Jariwala SP (2007) The role of dendritic cells in the immunopathogenesis of psoriasis. Arch Dermatol Res 299(8):359\u2013366","journal-title":"Arch Dermatol Res"},{"issue":"6","key":"2027_CR44","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1038\/jid.2015.56","volume":"135","author":"I Jozic","year":"2015","unstructured":"Jozic I, Stojadinovic O, Kirsner RS, Tomic-Canic M (2015) Skin under the (spot)-light: cross-talk with the central hypothalamic\u2013pituitary\u2013adrenal (HPA) axis. J Invest Dermatol 135(6):1469\u20131471","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2027_CR45","doi-asserted-by":"publisher","first-page":"329","DOI":"10.14218\/JCTH.2021.00178","volume":"10","author":"E Kaya","year":"2021","unstructured":"Kaya E, Yilmaz Y (2021) Metabolic-associated fatty liver disease (MAFLD): a multi-systemic disease beyond the liver. J Clin Transl Hepatol 10(2):329","journal-title":"J Clin Transl Hepatol"},{"key":"2027_CR46","unstructured":"Keskin S, A\u00c7IKG\u00d6Z E. Role of keratinocytes and immune cells as key actors in psoriasis. International Research and Reviews in Health Sciences. 2023:201."},{"issue":"7","key":"2027_CR47","doi-asserted-by":"publisher","first-page":"6390","DOI":"10.3390\/ijms24076390","volume":"24","author":"K Kie\u0142bowski","year":"2023","unstructured":"Kie\u0142bowski K, Bakinowska E, Ostrowski P, Pala B, Gromowska E, Gurazda K et al (2023) The role of adipokines in the pathogenesis of psoriasis. Int J Mol Sci 24(7):6390","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2027_CR48","doi-asserted-by":"publisher","first-page":"468","DOI":"10.5114\/ada.2019.83983","volume":"37","author":"EH K\u0142ujszo","year":"2020","unstructured":"K\u0142ujszo EH, Parcheta P, Witkowska AB, Kr\u0119cisz B (2020) Non-alcoholic fatty liver disease in patients with psoriasis-therapeutic implications. Adv Dermatol Allergol 37(4):468\u2013474","journal-title":"Adv Dermatol Allergol"},{"key":"2027_CR49","unstructured":"Kolar K (2023) Cross-sectional study of liver fibrosis in psoriatic patients using ultrasound shear wave elastography: Sri Devaraj URS Medical College"},{"issue":"4","key":"2027_CR50","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjd.18245","volume":"182","author":"N Korman","year":"2020","unstructured":"Korman N (2020) Management of psoriasis as a systemic disease: what is the evidence? Br J Dermatol 182(4):840\u2013848","journal-title":"Br J Dermatol"},{"key":"2027_CR51","volume-title":"Treatment of skin disease E-Book: comprehensive therapeutic strategies","author":"MG Lebwohl","year":"2013","unstructured":"Lebwohl MG, Heymann WR, Berth-Jones J, Coulson I (2013) Treatment of skin disease E-Book: comprehensive therapeutic strategies. Elsevier Health Sciences, Amsterdam"},{"issue":"17","key":"2027_CR52","doi-asserted-by":"publisher","first-page":"13313","DOI":"10.3390\/ijms241713313","volume":"24","author":"H-J Lee","year":"2023","unstructured":"Lee H-J, Kim M (2023) Challenges and future trends in the treatment of psoriasis. Int J Mol Sci 24(17):13313","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2027_CR53","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1177\/2475530318810851","volume":"4","author":"SJ Li","year":"2019","unstructured":"Li SJ, Perez-Chada LM, Merola JF (2019) TNF inhibitor-induced psoriasis: proposed algorithm for treatment and management. J Psoriasis Psoriatic Arthritis 4(2):70\u201380","journal-title":"J Psoriasis Psoriatic Arthritis"},{"issue":"5","key":"2027_CR54","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s12026-020-09149-1","volume":"68","author":"B Li","year":"2020","unstructured":"Li B, Huang L, Lv P, Li X, Liu G, Chen Y et al (2020) The role of Th17 cells in psoriasis. Immunol Res 68(5):296\u2013309","journal-title":"Immunol Res"},{"issue":"10","key":"2027_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293327","volume":"18","author":"X-Q Liu","year":"2023","unstructured":"Liu X-Q, Zhou P-L, Yin X-Y, Wang A-X, Wang D-H, Yang Y et al (2023) Circulating inflammatory cytokines and psoriasis risk: a systematic review and meta-analysis. PLoS ONE 18(10):e0293327","journal-title":"PLoS ONE"},{"issue":"1","key":"2027_CR56","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1146\/annurev-immunol-032713-120225","volume":"32","author":"MA Lowes","year":"2014","unstructured":"Lowes MA, Suarez-Farinas M, Krueger JG (2014) Immunology of psoriasis. Annu Rev Immunol 32(1):227\u2013255","journal-title":"Annu Rev Immunol"},{"issue":"1","key":"2027_CR57","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1684\/ejd.2024.4610","volume":"34","author":"J Ma","year":"2024","unstructured":"Ma J, Sun X, Wu Z, Qi R, Niu J (2024) Correlation between the systemic immune inflammation index and risk of psoriasis: results from NHANES. Eur J Dermatol 34(1):31\u201339","journal-title":"Eur J Dermatol"},{"issue":"12","key":"2027_CR58","doi-asserted-by":"publisher","first-page":"900","DOI":"10.14260\/jemds\/2020\/194","volume":"9","author":"BR Manchiryala","year":"2020","unstructured":"Manchiryala BR, Tirupathi UR, Anand T (2020) Psoriasis and its association with various biochemical parameters: A clinico-epidemiological study. J Evol Med Dent Sci 9(12):900\u2013905","journal-title":"J Evol Med Dent Sci"},{"issue":"2","key":"2027_CR59","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/ijms17020217","volume":"17","author":"A Mantovani","year":"2016","unstructured":"Mantovani A, Gisondi P, Lonardo A, Targher G (2016) Relationship between non-alcoholic fatty liver disease and psoriasis: a novel hepato-dermal axis? Int J Mol Sci 17(2):217","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2027_CR60","first-page":"13","volume":"12","author":"G Martin","year":"2019","unstructured":"Martin G, Young M, Aldredge L (2019) Recommendations for initiating systemic therapy in patients with psoriasis. J Clin Aesthet Dermatol 12(4):13","journal-title":"J Clin Aesthet Dermatol"},{"issue":"4","key":"2027_CR61","doi-asserted-by":"publisher","first-page":"796","DOI":"10.3390\/cells9040796","volume":"9","author":"AM Martins","year":"2020","unstructured":"Martins AM, Ascenso A, Ribeiro HM, Marto J (2020) The brain\u2013skin connection and the pathogenesis of psoriasis: a review with a focus on the serotonergic system. Cells 9(4):796","journal-title":"Cells"},{"key":"2027_CR62","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.665647","volume":"8","author":"L Mercurio","year":"2021","unstructured":"Mercurio L, Albanesi C, Madonna S (2021) Recent updates on the involvement of PI3K\/AKT\/mTOR molecular cascade in the pathogenesis of hyperproliferative skin disorders. Front Med 8:665647","journal-title":"Front Med"},{"issue":"1","key":"2027_CR63","doi-asserted-by":"publisher","first-page":"1886844","DOI":"10.1080\/19490976.2021.1886844","volume":"13","author":"AH Mohseni","year":"2021","unstructured":"Mohseni AH, Casolaro V, Berm\u00fadez-Humar\u00e1n LG, Keyvani H, Taghinezhad-S S (2021) Modulation of the PI3K\/Akt\/mTOR signaling pathway by probiotics as a fruitful target for orchestrating the immune response. Gut Microbes 13(1):1886844","journal-title":"Gut Microbes"},{"key":"2027_CR64","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1468-3083.2011.03991.x","volume":"25","author":"H Montaudi\u00e9","year":"2011","unstructured":"Montaudi\u00e9 H, Sbidian E, Paul C, Maza A, Gallini A, Aractingi S et al (2011) Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol 25:12\u201318","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"2027_CR65","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1111\/1346-8138.14213","volume":"45","author":"A Morita","year":"2018","unstructured":"Morita A (2018) Current developments in phototherapy for psoriasis. J Dermatol 45(3):287\u2013292","journal-title":"J Dermatol"},{"key":"2027_CR66","doi-asserted-by":"crossref","unstructured":"N\u00e4slund-Koch C, Kaiser H, Skov L, editors. Comorbidity in adult psoriasis. IFPA-WPPAC 2021; 2023.","DOI":"10.55788\/723a4c4c"},{"issue":"2","key":"2027_CR67","doi-asserted-by":"publisher","first-page":"503","DOI":"10.47162\/RJME.61.2.20","volume":"61","author":"C-D Neagoe","year":"2020","unstructured":"Neagoe C-D, Farmazon A-S, Amzolini A-M, Singer C-E, Iano\u015fi S-L, Tutunaru C-V et al (2020) The role of non-invasive scores in determining the liver fibrosis in NAFLD and psoriatic patients. Rom J Morphol Embryol 61(2):503","journal-title":"Rom J Morphol Embryol"},{"issue":"1","key":"2027_CR68","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/1523-1747.ep12477880","volume":"97","author":"P Neuner","year":"1991","unstructured":"Neuner P, Urbanski A, Trautinger F, M\u00f6ller A, Kirnbauer R, Kapp A et al (1991) Increased IL-6 production by monocytes and keratinocytes in patients with psoriasis. J Invest Dermatol 97(1):27\u201333","journal-title":"J Invest Dermatol"},{"issue":"8","key":"2027_CR69","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.3390\/ijms22083998","volume":"22","author":"I Olejniczak-Staruch","year":"2021","unstructured":"Olejniczak-Staruch I, Ci\u0105\u017cy\u0144ska M, Sobolewska-Sztychny D, Narbutt J, Skibi\u0144ska M, Lesiak A (2021) Alterations of the skin and gut microbiome in psoriasis and psoriatic arthritis. Int J Mol Sci 22(8):3998","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2027_CR70","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3390\/life13020419","volume":"13","author":"A Olveira","year":"2023","unstructured":"Olveira A, Augustin S, Benlloch S, Ampuero J, Su\u00e1rez-P\u00e9rez JA, Armesto S et al (2023) The essential role of IL-17 as the pathogenetic link between psoriasis and metabolic-associated fatty liver disease. Life 13(2):419","journal-title":"Life"},{"issue":"6","key":"2027_CR71","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.cytogfr.2010.10.007","volume":"21","author":"W Ouyang","year":"2010","unstructured":"Ouyang W (2010) Distinct roles of IL-22 in human psoriasis and inflammatory bowel disease. Cytokine Growth Factor Rev 21(6):435\u2013441","journal-title":"Cytokine Growth Factor Rev"},{"issue":"2","key":"2027_CR72","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s40257-017-0322-9","volume":"19","author":"MC Ovejero-Benito","year":"2018","unstructured":"Ovejero-Benito MC, Munoz-Aceituno E, Reolid A, Saiz-Rodriguez M, Abad-Santos F, Dauden E (2018) Pharmacogenetics and pharmacogenomics in moderate-to-severe psoriasis. Am J Clin Dermatol 19(2):209\u2013222","journal-title":"Am J Clin Dermatol"},{"key":"2027_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109341","volume":"113","author":"S Parab","year":"2022","unstructured":"Parab S, Doshi G (2022) An update on emerging immunological targets and their inhibitors in the treatment of psoriasis. Int Immunopharmacol 113:109341","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"2027_CR74","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s13679-020-00380-3","volume":"9","author":"K Paroutoglou","year":"2020","unstructured":"Paroutoglou K, Papadavid E, Christodoulatos GS, Dalamaga M (2020) Deciphering the association between psoriasis and obesity: current evidence and treatment considerations. Curr Obes Rep 9(3):165\u2013178","journal-title":"Curr Obes Rep"},{"key":"2027_CR75","unstructured":"Pawluk MA, Cederberg RA, Zhao H, Jung K, Burleigh A, Crawford RI. keratinocyte proliferation. Immune Regulations of Inflammatory Skin Diseases. 2024:95."},{"issue":"16","key":"2027_CR76","doi-asserted-by":"publisher","first-page":"9063","DOI":"10.3390\/ijms23169063","volume":"23","author":"S Piaserico","year":"2022","unstructured":"Piaserico S, Orlando G, Messina F (2022) Psoriasis and cardiometabolic diseases: shared genetic and molecular pathways. Int J Mol Sci 23(16):9063","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2027_CR77","doi-asserted-by":"publisher","first-page":"7","DOI":"10.2174\/18734316MTA35NzY65","volume":"22","author":"G Radi","year":"2021","unstructured":"Radi G, Campanati A, Diotallevi F, Bianchelli T, Offidani A (2021) Novel therapeutic approaches and targets for treatment of psoriasis. Curr Pharm Biotechnol 22(1):7\u201331","journal-title":"Curr Pharm Biotechnol"},{"key":"2027_CR78","unstructured":"Rahman1 M, Yashika MK, Anurag4 OS. A Review on Psoriasis. NeuroQuantology. 2022;20(16):5786\u201393."},{"key":"2027_CR79","doi-asserted-by":"crossref","unstructured":"Rajagopalan M, Dogra S, Saraswat A, Varma S, Banodkar P. The use of apremilast in psoriasis: an Indian perspective on real-world scenarios. Psoriasis: Targets and Therapy. 2021:109\u201322.","DOI":"10.2147\/PTT.S320810"},{"key":"2027_CR80","doi-asserted-by":"publisher","DOI":"10.1615\/critrevtherdrugcarriersyst.2013005268","author":"AS Raut","year":"2013","unstructured":"Raut AS, Prabhu RH, Patravale VB (2013) Psoriasis clinical implications and treatment: a review. Crit Rev Ther Drug Carrier Syst. https:\/\/doi.org\/10.1615\/critrevtherdrugcarriersyst.2013005268","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"issue":"3","key":"2027_CR81","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2340\/00015555-3386","volume":"100","author":"C Reid","year":"2020","unstructured":"Reid C, Griffiths CE (2020) Psoriasis and treatment: past, present and future aspects. Acta Dermato-Venereol 100(3):69\u201379","journal-title":"Acta Dermato-Venereol"},{"issue":"6","key":"2027_CR82","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","volume":"20","author":"A Rendon","year":"2019","unstructured":"Rendon A, Sch\u00e4kel K (2019) Psoriasis pathogenesis and treatment. Int J Mol Sci 20(6):1475","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2027_CR83","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.3390\/ijms25021042","volume":"25","author":"L Rusi\u00f1ol","year":"2024","unstructured":"Rusi\u00f1ol L, Puig L (2024) Multi-omics approach to improved diagnosis and treatment of atopic dermatitis and psoriasis. Int J Mol Sci 25(2):1042","journal-title":"Int J Mol Sci"},{"key":"2027_CR84","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3389\/fimmu.2018.01323","volume":"9","author":"MP Sch\u00f6n","year":"2018","unstructured":"Sch\u00f6n MP, Erpenbeck L (2018) The interleukin-23\/interleukin-17 axis links adaptive and innate immunity in psoriasis. Front Immunol 9:1323","journal-title":"Front Immunol"},{"issue":"4","key":"2027_CR85","first-page":"363","volume":"21","author":"MP Sch\u00f6n","year":"2023","unstructured":"Sch\u00f6n MP, Wilsmann-Theis D (2023) Current developments and perspectives in psoriasis. JDDG J Dtsch Dermatol Ges 21(4):363\u2013372","journal-title":"JDDG J Dtsch Dermatol Ges"},{"issue":"15","key":"2027_CR86","doi-asserted-by":"publisher","first-page":"8462","DOI":"10.3390\/ijms25158462","volume":"25","author":"CM Sergi","year":"2024","unstructured":"Sergi CM (2024) NAFLD (MASLD)\/NASH (MASH): does it bother to label at all? A comprehensive narrative review. Int J Mol Sci 25(15):8462","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2027_CR87","doi-asserted-by":"publisher","first-page":"24","DOI":"10.2174\/2589977513666210707114520","volume":"14","author":"A Sharma","year":"2022","unstructured":"Sharma A, Upadhyay DK, Gupta GD, Narang RK, Rai VK (2022) IL-23\/Th17 axis: a potential therapeutic target of psoriasis. Curr Drug Res Rev 14(1):24\u201336","journal-title":"Curr Drug Res Rev"},{"issue":"6","key":"2027_CR88","first-page":"e235","volume":"180","author":"J Sheu","year":"2019","unstructured":"Sheu J, Tran J, Rady P, Dao H Jr, Tyring S, Nguyen H (2019) Polyomaviruses of the skin. British J Dermatol. 180(6):e235","journal-title":"British J Dermatol."},{"issue":"15","key":"2027_CR89","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.2174\/1389450122666210118103455","volume":"22","author":"A Singh","year":"2021","unstructured":"Singh A, Easwari T (2021) Recent advances in psoriasis therapy: trends and future prospects. Curr Drug Targets 22(15):1760\u20131771","journal-title":"Curr Drug Targets"},{"issue":"2","key":"2027_CR90","doi-asserted-by":"publisher","first-page":"663","DOI":"10.3390\/jcm12020663","volume":"12","author":"S S\u0142uczanowska-G\u0142abowska","year":"2023","unstructured":"S\u0142uczanowska-G\u0142abowska S, Staniszewska M, Marchlewicz M, Duchnik E, \u0141uczkowska K, Safranow K et al (2023) Adiponectin, leptin and resistin in patients with psoriasis. J Clin Med 12(2):663","journal-title":"J Clin Med"},{"issue":"3","key":"2027_CR91","first-page":"2733","volume":"18","author":"W Sun","year":"2018","unstructured":"Sun W, Gao Y, Yu X, Yuan Y, Yi J, Zhang Z et al (2018) \u2018Psoriasis 1\u2019reduces psoriasis-like skin inflammation by inhibiting the VDR-mediated nuclear NF-\u03baB and STAT signaling pathways. Mol Med Rep 18(3):2733\u20132743","journal-title":"Mol Med Rep"},{"issue":"1","key":"2027_CR92","volume":"2019","author":"L Sun","year":"2019","unstructured":"Sun L, Liu W, Zhang L-j (2019) The role of toll-like receptors in skin host defense, psoriasis, and atopic dermatitis. J Immunol Res 2019(1):1824624","journal-title":"J Immunol Res"},{"issue":"3","key":"2027_CR93","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","volume":"76","author":"J Takeshita","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, Mehta NN, Ogdie A, Van Voorhees AS et al (2017) Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol 76(3):377\u2013390","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"2027_CR94","doi-asserted-by":"publisher","first-page":"4457","DOI":"10.3390\/ijms23084457","volume":"23","author":"T Tashiro","year":"2022","unstructured":"Tashiro T, Sawada Y (2022) Psoriasis and systemic inflammatory disorders. Int J Mol Sci 23(8):4457","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2027_CR95","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1007\/s40257-021-00603-w","volume":"22","author":"A Thatiparthi","year":"2021","unstructured":"Thatiparthi A, Martin A, Liu J, Egeberg A, Wu JJ (2021) Biologic treatment algorithms for moderate-to-severe psoriasis with comorbid conditions and special populations: a review. Am J Clin Dermatol 22(4):425\u2013442","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"2027_CR96","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.3390\/biomedicines10051037","volume":"10","author":"AY-K Thye","year":"2022","unstructured":"Thye AY-K, Bah Y-R, Law JW-F, Tan LT-H, He Y-W, Wong S-H et al (2022) Gut\u2013skin axis: unravelling the connection between the gut microbiome and psoriasis. Biomedicines. 10(5):1037","journal-title":"Biomedicines."},{"issue":"7","key":"2027_CR97","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1080\/13543784.2016.1187130","volume":"25","author":"T Torres","year":"2016","unstructured":"Torres T, Romanelli M, Chiricozzi A (2016) A revolutionary therapeutic approach for psoriasis: bispecific biological agents. Expert Opin Investig Drugs 25(7):751\u2013754","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"2027_CR98","doi-asserted-by":"publisher","first-page":"235","DOI":"10.4103\/2229-5178.209622","volume":"8","author":"R Torsekar","year":"2017","unstructured":"Torsekar R, Gautam MM (2017) Topical therapies in psoriasis. Indian Dermatol Online J 8(4):235\u2013245","journal-title":"Indian Dermatol Online J"},{"issue":"1","key":"2027_CR99","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2174\/187221309787158399","volume":"3","author":"D Tsuruta","year":"2009","unstructured":"Tsuruta D (2009) NF-\u03baB links keratinocytes and lymphocytes in the pathogenesis of psoriasis. Recent Pat Inflamm Allergy Drug Discov 3(1):40\u201348","journal-title":"Recent Pat Inflamm Allergy Drug Discov"},{"key":"2027_CR100","first-page":"1","volume-title":"AI in psoriatic disease (\u201cPsAI\u201d): Current insights and future directions","author":"V Venerito","year":"2025","unstructured":"Venerito V, Proft F (2025) AI in psoriatic disease (\u201cPsAI\u201d): Current insights and future directions. Springer, Berlin, pp 1\u20135"},{"issue":"4","key":"2027_CR101","doi-asserted-by":"publisher","first-page":"2258","DOI":"10.1007\/s10753-024-02188-y","volume":"48","author":"D Wang","year":"2025","unstructured":"Wang D, Tang W, Sun N, Cao K, Li Q, Li S et al (2025) Uncovering the mechanism of Scopoletin in ameliorating psoriasis-like skin symptoms via inhibition of PI3K\/Akt\/mTOR signaling pathway. Inflammation 48(4):2258\u20132273","journal-title":"Inflammation"},{"issue":"4","key":"2027_CR102","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/j.1468-3083.2010.03841.x","volume":"25","author":"K Wenk","year":"2011","unstructured":"Wenk K, Arrington K, Ehrlich A (2011) Psoriasis and non-alcoholic fatty liver disease. J Eur Acad Dermatol Venereol 25(4):383\u2013391","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"2027_CR103","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1111\/1346-8138.15913","volume":"48","author":"K Yamanaka","year":"2021","unstructured":"Yamanaka K, Yamamoto O, Honda T (2021) Pathophysiology of psoriasis: a review. J Dermatol 48(6):722\u2013731","journal-title":"J Dermatol"},{"issue":"1","key":"2027_CR104","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3892\/mmr.2024.13239","volume":"30","author":"J-S Yang","year":"2024","unstructured":"Yang J-S, Liu T-Y, Lu H-F, Tsai S-C, Liao W-L, Chiu Y-J et al (2024) Genome-wide association study and polygenic risk scores predict psoriasis and its shared phenotypes in Taiwan. Mol Med Rep 30(1):1\u201322","journal-title":"Mol Med Rep"},{"issue":"8","key":"2027_CR105","doi-asserted-by":"publisher","first-page":"754","DOI":"10.3390\/medicina57080754","volume":"57","author":"N Zdanowska","year":"2021","unstructured":"Zdanowska N, Kasprowicz-Furma\u0144czyk M, Placek W, Owczarczyk-Saczonek A (2021) The role of chemokines in psoriasis: an overview. Medicina 57(8):754","journal-title":"Medicina"},{"issue":"2","key":"2027_CR106","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s00403-018-1879-8","volume":"311","author":"M Zhang","year":"2019","unstructured":"Zhang M, Zhang X (2019) The role of PI3K\/AKT\/FOXO signaling in psoriasis. Arch Dermatol Res 311(2):83\u201391","journal-title":"Arch Dermatol Res"},{"issue":"1","key":"2027_CR107","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12866-021-02125-1","volume":"21","author":"X Zhang","year":"2021","unstructured":"Zhang X, Shi L, Sun T, Guo K, Geng S (2021) Dysbiosis of gut microbiota and its correlation with dysregulation of cytokines in psoriasis patients. BMC Microbiol 21(1):78","journal-title":"BMC Microbiol"},{"issue":"11","key":"2027_CR108","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-074752","volume":"13","author":"X-j Zhang","year":"2023","unstructured":"Zhang X-j, Lin J, Feng L, Ou M, Gong F-q (2023) Non-pharmacological interventions for patients with psoriasis: a scoping review. BMJ Open 13(11):e074752","journal-title":"BMJ Open"},{"issue":"6","key":"2027_CR109","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-024-02972-8","volume":"316","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Qian H, Kuang Y-h, Wang Y, Chen W-q, Zhu W (2024a) Evaluation of the inflammatory parameters as potential biomarkers of systemic inflammation extent and the disease severity in psoriasis patients. Arch Dermatol Res 316(6):229","journal-title":"Arch Dermatol Res"},{"key":"2027_CR110","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S454798","author":"X Zhang","year":"2024","unstructured":"Zhang X, Du H, Liu X, Liu L, Zhang T (2024b) Knowledge, attitudes and practices towards psoriasis among patients and their family members. Clin Cosmet Investig Dermatol. https:\/\/doi.org\/10.2147\/CCID.S454798","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"10","key":"2027_CR111","doi-asserted-by":"publisher","DOI":"10.1002\/iid3.70050","volume":"12","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Bai YP, Li LF (2024) Association between systemic immune-inflammation index and psoriasis, psoriasis comorbidities, and all-cause mortality: a study based on NHANES. Immunity Inflamm Dis 12(10):e70050","journal-title":"Immunity Inflamm Dis"},{"issue":"7","key":"2027_CR112","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.freeradbiomed.2009.06.033","volume":"47","author":"Q Zhou","year":"2009","unstructured":"Zhou Q, Mrowietz U, Rostami-Yazdi M (2009) Oxidative stress in the pathogenesis of psoriasis. Free Radical Biol Med 47(7):891\u2013905","journal-title":"Free Radical Biol Med"},{"issue":"1","key":"2027_CR113","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","volume":"13","author":"X Zhou","year":"2022","unstructured":"Zhou X, Chen Y, Cui L, Shi Y, Guo C (2022) Advances in the pathogenesis of psoriasis: from keratinocyte perspective. Cell Death Dis 13(1):81","journal-title":"Cell Death Dis"},{"key":"2027_CR114","doi-asserted-by":"publisher","first-page":"1430586","DOI":"10.3389\/fcimb.2024.1430586","volume":"14","author":"X Zou","year":"2024","unstructured":"Zou X, Zou X, Gao L, Zhao H (2024) Gut microbiota and psoriasis: pathogenesis, targeted therapy, and future directions. Front Cell Infect Microbiol 14:1430586","journal-title":"Front Cell Infect Microbiol"}],"container-title":["Inflammopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02027-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10787-025-02027-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10787-025-02027-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T20:04:14Z","timestamp":1773777854000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10787-025-02027-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":114,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2027"],"URL":"https:\/\/doi.org\/10.1007\/s10787-025-02027-y","relation":{},"ISSN":["0925-4692","1568-5608"],"issn-type":[{"value":"0925-4692","type":"print"},{"value":"1568-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"assertion":[{"value":"31 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable. This article does not contain any studies involving human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}